BCG-ревакцинации для предотвращения туберкулезной инфекции и автоматизированной доставке инсулина при диабете 2-го типа

Туберкулез остается глобальной проблемой, несмотря на вакцину BCG [1]. Исследования, включая NEJM (2025) [2], показывают противоречивые данные об эффективности BCG-ревакцинации. Автоматизированная доставка инсулина (AID) улучшает контроль диабета 2-го типа [3]. Статья анализирует клинические испытания и иммунологические аспекты BCG-ревакцинации, а также эффективность AID. Основа: систематический обзор (Cochrane, PubMed, Scopus). Объем: 7 страниц, 20 источников. Статья писалась по требованиям "Медицинского вестника"

1. WHO. BCG Vaccines: WHO Position Paper – February 2018. Wkly Epidemiol Rec. 2018;8:73–96.

2. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. 2025.

3. Pozzilli P. BCG Vaccine in Insulin-Dependent Diabetes Mellitus. Lancet. 1997;349:1520–1521.

4. Harris RJ, et al. Effect of BCG Vaccination Against Mycobacterium tuberculosis Infection in Children: Systematic Review and Meta-analysis. BMJ. 2014;349:g4643.

5. Nemes E, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379(2):138-149.

6. WHO. Global Tuberculosis Report 2023. Geneva: World Health Organization; 2023.

7. Ferreira AA. BCG Vaccine: Efficacy and Indications for Vaccination and Revaccination. J Pediatr. 2006;82:45–54.

8. Dos Santos P, et al. BCG Revaccination and Tuberculosis Infection: A Randomized Controlled Trial. Lancet Infect Dis. 2025.

9. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.

10. Rodrigues LC. Modern Vaccines: Mycobacterial Diseases. Lancet. 1990;335:1016-20.

11. Bekker L, et al. Safety and Immunological Responses to BCG Revaccination in Adolescents. EClinicalMedicine. 2020;21:100313.

12. Cochrane Review: Interventions for Improving Glycaemic Control in Type 2 Diabetes. 2023.

13. Boshoff HI. The Spectrum of Latent Tuberculosis: Rethinking the Goals of Prophylaxis. Nat Rev Microbiol. 2009;7:845-855.

14. Ximenes R, et al. BCG Vaccine Against Tuberculosis: Its Protective Effect and Vaccination Policies. Rev Saude Publica. 2007;41:59–66.

15. Van Der Meeren O, et al. M72/AS01E Tuberculosis Vaccine Efficacy. N Engl J Med. 2018;379:1621-1634.

16. Sorensen RU. Case-Control Study of the Efficacy of BCG Immunization Against Pulmonary Tuberculosis in Young Adults in Santiago, Chile. Tubercle Lung Dis. 1992;73:372–7.

17. Tursunbayeva A, et al. Comparative Tuberculosis (TB) Prevention Effectiveness in Children of Bacillus Calmette-Guerin (BCG) Vaccines from Different Sources, Kazakhstan. PLoS ONE. 2012;7(3):e32567.

18. Bishai WR. BCG Turns 100: Its Nontraditional Uses Against Viruses, Cancer, and Immunologic Diseases. J Clin Invest. 2021;131:1-11.

19. Allen HF, et al. Effect of Bacillus Calmette-Guerin Vaccination on New-Onset Type 1 Diabetes. Diabetes Care. 1999;22:1703–1707.

20. Ban L, et al. Selective Death of Autoreactive T Cells in Human Diabetes by TNF or TNF Receptor 2 Agonism. Proc Natl Acad Sci USA. 2008;105:13644–13649.